Longevity Biomedical, Inc. And Denali Capital Acquisition Corp. Announce Business Combination
Longevity Biomedical, Inc. And Denali Capital Acquisition Corp. Announce Business Combination
長壽生醫股份有限公司與德納利資本收購股份有限公司宣佈業務合
- Longevity Biomedical is focused on developing and acquiring new technologies spanning therapeutics, health monitoring and digital health solutions to become a leading provider of longevity-related products and services designed to increase health span for the rapidly growing global aging population.
- Late-stage, diversified pipeline of therapeutic candidates across ophthalmology, cardiovascular disease and soft tissue reconstruction and repair.
- Total proceeds expected to bring minimum pro forma cash balance of $30 million with cash runway into 2025.
- Near-term clinical milestones include Phase 3 start for LBI-201 for Ischemic stroke, Phase 2 data for LBI-101 for soft-tissue reconstruction, Phase 2 start for LBI-001 in retinal vein occlusion, and completion of preclinical and formulation studies for LBI-002 in corneal blindness.
- Seasoned management team of medtech and biopharmaceutical veterans with track record of acquiring, developing and commercializing novel technologies.
- Post-combination company to list on Nasdaq under ticker symbol "LBIO."
- Business combination expected to close in Q2 2023.
- L壽生醫專注開發/獲治療科技/健康監測/數位健康解決方案的新技術, 成為長壽相關產品和服務的領先供應商, 旨在為快速增長的全球老齡化人口增加健康範圍。
- 晚期，多樣化的治療候選人管道，涵蓋眼科，心血管疾病和軟組織重建和修復。
- 預計收益總額將帶來最低備考現金餘額 3,000 萬美元，並將現金跑道帶入 2025 年。
- 近期臨床里程碑包括 LBI-201 缺血性中風的第三期開始、LBI-101 用於軟組織重建的第二期數據、LBI-001 在視網膜靜脈閉合的 2 期開始，以及完成 LBI-002 角膜失明的臨床前和配方研究。
- 由醫療科技和生物製藥資深人士組成的經驗豐富的管理團隊，在獲取、開發和商業化新技術方面擁有良好記錄。
- 合併後公司將在納斯達克上市，股票代號為 LBIO。
- 業務合併預計將於 2023 年第二季關閉。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。